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We previously demonstrated that, in the early stages of tau processing in Alzheimer’s
disease, the N-terminal part of the molecule undergoes a characteristic cascade of
phosphorylation and progressive misfolding of the proteins resulting in a structural
conformation detected by Alz-50. In this immunohistochemical study of AD brain tissue,
we have found that C-terminal truncation of tau at Asp-421 was an early event in tau
aggregation and analyzed the relationship between phospho-dependent tau epitopes
located at the C-terminus with truncation at Glu-391. The aim of this study was to
determine whether C-terminal truncation may trigger events leading to the assembly
of insoluble PHFs from soluble tau aggregates present in pre-tangle cells. Our findings
suggest that there is a complex interaction between phosphorylated and truncated tau
species. A model is presented here in which truncated tau protein represents an early
neurotoxic species while phosphorylated tau species may provide a neuroprotective role
in Alzheimer’s disease.
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INTRODUCTION
Tau pathology, a principal hallmark of Alzheimer’s disease, is
characterized by abnormal hyperphosphorylation and truncation
of tau proteins (Wischik et al., 1988a; Goedert et al., 1992; Novak
et al., 1993; Mena et al., 1996). Both molecular events are asso-
ciated with the formation of paired helical filaments (PHFs) and
the appearance of the neurofibrillary tangles (NFTs) within the
cytoplasm of vulnerable cells (Wischik et al., 1988b; Novak et al.,
1993; Mena et al., 1995, 1996; Guillozet-Bongaarts et al., 2005;
Luna-Munoz et al., 2007). Although it has been suggested that
phosphorylation of tau is associated with PHF assembly, evidence
to confirm this has not been substantiated, since these studies
have been based upon in vitro experiments and animal mod-
els rather than Alzheimer’s disease tissue (Alonso et al., 1996,
2001). Wischik and colleagues demonstrated that the insoluble
PHF consists of a protease-resistant core that retains the char-
acteristic structural features of the intact PHF after Pronase
digestion, but lacks a fuzzy outer coat (Wischik et al., 1988a,b;
Novak et al., 1993). The tau fragment within the PHF core,
corresponds to a sequence of 93–95 amino acids in length that
are C-terminally truncated at Glu-391 (Wischik et al., 1988a;
Novak et al., 1993). PHFs can be distinguished by their differen-
tial solubility.While sarkosyl-soluble PHFs are mainly constituted
of tau protein in a hyperphosphorylated state, insoluble PHF
fractions from Alzheimer’s disease brains are Pronase resistant
and phosphorylated tau accounts for no more than 15% of
the content of such PHFs (Wischik et al., 1995). Furthermore,
rather than promoting the aggregation of tau, phosphorylation
of tau is inhibitory for aggregation in vitro (Schneider et al.,
1999).
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The monoclonal antibody (mAb) 423 specifically identifies
the C-terminal truncation of tau at Glu-391 in Alzheimer’s dis-
ease brains (Novak, 1994). We have demonstrated that mAb
423-immunoreactive deposits are present in both intra- and
extra-cellular NFTs (Mena et al., 1991, 1995; Garcia-Sierra et al.,
2003; Luna-Munoz et al., 2007). Furthermore, C-terminally trun-
cated tau protein has a greater affinity for binding full-length tau
molecules (Abraha et al., 2000; Berry et al., 2003) and core PHF-
tau over-expressed in transfected COS cells induces apoptosis
(Fasulo et al., 1998).
We have combined the techniques of double- and triple-
labeled immunohistochemistry with confocal microscopy to
examine the molecular changes that arise in pre-tangle cells
(Luna-Munoz et al., 2005, 2007). Such cells display the major-
ity of epitopes present in PHFs but in the absence of cytoplasmic
fibrillary structures. Examining pre-tangle cells has enabled us
to study stages of phosphorylation along the N-portion of tau
protein in Alzheimer’s disease (Luna-Munoz et al., 2007). In par-
ticular, we used four phospho-dependent tau antibodies, namely
p-231, TG-3, AT8, and AT100. In addition tomAb 423, TauC3was
used to identify C-terminal truncation of the protein at Asp-421
(Gamblin et al., 2003c; Guillozet-Bongaarts et al., 2005; Luna-
Munoz et al., 2007; Basurto-Islas et al., 2008). Early stages of
tau processing in pre-tangle cells are characterized by a specific
cascade of events in which phosphorylation of the N-terminal
domain of tau plays a major role. In addition, we found that
Asp-421 truncation at the C-terminus of tau molecule is also
present at early stages of tau aggregation (Luna-Munoz et al.,
2007).
In this study, we have analyzed the relationship between phos-
phorylation and truncation in pre-tangle cells. Under normal
conditions, truncation at Glu-391 is not detected in aggregates of
tau within the cytoplasm of pre-tangle cells. We discuss the con-
sequences of the presence of a highly toxic PHF core in the early
stages of tau processing in Alzheimer’s disease and discuss how
phosphorylated tau may act in a protective manner against the
toxicity of the PHF core.
MATERIALS AND METHODS
BRAIN TISSUE
Brain tissue from six Alzheimer’s disease patients (Table 1) was
examined in this study (ages, 47–93 years; mean 78.33 years; 2–6 h
post-mortem delays) All tissues were obtained from the Brain
Bank-LaNSE CINVESTAV-IPN, Mexico in accordance with the
institutional bioethics guidelines. The diagnosis of Alzheimer’s
disease was obtained using the NINCDS-ADRDA group crite-
ria (McKhann et al., 1984), and all samples were Braak stages
5–6. Blocks of hippocampus and adjacent entorhinal cortex
were fixed by immersion in a solution of 4% paraformalde-
hyde in phosphate-buffered saline (PBS), pH 7.4, at 4◦C for
7 days.
ANTIBODIES
The characteristics of the antibodies used in this study are listed in
Table 2 and the location of their epitopes shown in the schematic
representation of tau protein in Figure 1.
IMMUNOFLUORESCENCE
Free-floating sections (50μm-thick) were exposed to Pronase
(0.05% diluted in PBS; Type XIV, Sigma, St Louis, Mo) at 37◦C
for 30min, washed with PBS then formic acid (98–100%; Merck,
Germany) at room temperature for 3min. Sections were blocked
with a solution of 0.2% IgG-free albumin (Sigma Chemical Co.)
in PBS for 20min at room temperature. Sections were then incu-
bated with the primary antibodies pS396 and mAb 423 (both
are IgG subtypes) overnight at 4◦C, and then with FITC-tagged
goat-anti-rabbit IgG secondary antibody and TRITC-tagged goat-
anti-Mouse IgGγ secondary antibody (Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA). PBS containing 0.2% Triton
X-100 (Sigma Chemical Co.) solution was used in all of the
immunolabeling steps for 1 h. Primary antibodies were used at
the dilutions indicated in Table 2).
Triple immunolabeling was performed using different combi-
nations. (a) Alz-50 with AD2 and TG3. The corresponding sec-
ondary antibodies used were FITC-tagged goat-anti-rabbit IgG,
TRITC-tagged goat-anti-mouse IgGγ, and Cy5-tagged goat-anti-
mouse IgMμ, respectively. (b) For the combination of TauC3,
pS396, and TG-3, FITC-tagged goat-anti-mouse IgGγ, TRITC-
tagged goat-anti-rabbit IgG, and Cy5-tagged goat-anti-mouse
IgMμ where used. (c) Some sections were immunolabeled with
TauC3, AD2, and mAb 423 and counterstained with thiazin red
(for the staining of β-pleated structures). These three antibod-
ies are considered to detect late stages of tau processing in NFTs
(Galván et al., 2001; Garcia-Sierra et al., 2003, 2008). Control
sections were included in which incubations with Pronase and
formic acid were omitted. Selected sections were counterstained
with thiazin red (TR) to differentiate non-fibrillar from fibrillar
states of tau aggregates (Mena et al., 1995, 1996).
CONFOCAL MICROSCOPY
Double and triple immunolabeled sections were mounted
with anti-quenching media (Vectashield; Vector Laboratories,
Burlingame) and viewed through a confocal laser scan-
ning microscope (TCS-SP2, Leica, Heidelberg) using a
100× oil-immersion plan Apochromat objective (NA 1.4).
Ten to fifteen consecutive single sections were sequentially
scanned at 0.8–1.0μm intervals for two or three channels
throughout the z-axis of the sample. The resultant stack of
images was projected and analyzed onto the two-dimensional
plane using a pseudocolor display of green (FITC), red
Table 1 | Characteristics of the 6 Brain Samples used in this study.
Case # Brain area Sex Age (years)
1. Hippocampus CA1 M 80
2. Hippocampus CA1 F 90
3. Hippocampus CA1 M 81
4. Hippocampus CA1 F 47
5. Hippocampus CA1 F 93
6. Hippocampus CA1 M 79
All samples were Braak stages 5–6. Tissues were from the LANSE Brain Bank,
CINVESTAV, Mexico City.
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Table 2 | Tau-specific antibodies.
Antibody Tau epitope Species/sub-class Dilution References
(A) NON-PHOSPHORYLATED EPITOPES
Tau-12 N-terminal (residues 9-18) Mo/IgG 1:1000 (Horowitz et al., 2006)
T46 C-terminal (residues 404-441) Mo/IgG 1:100 (Preuss et al., 1995)
(B) CONFORMATIONAL EPITOPE
Alz-50 Conformational epitope (residues 5-15 and 312-322) Mo/IgM 1:500 (Carmel et al., 1996)
(C) PHOSPHO-DEPENDENT N-TERMINAL EPITOPE
TG-3 p-Thr-231 Mo/IgM 1:60 (Jicha et al., 1997b)
(D) PHOSPHO-DEPENDENT C-TERMINAL EPITOPES
pS396 p-Ser-396 Rb/IgG 1:500 (Bramblett et al., 1993)
pS400 p-Ser-400 Rb/IgG 1:100 (Liu et al., 2005)
pS404 p-Ser-404 Rb/IgG 1:100 (Augustinack et al., 2002)
pS409 p-Ser-409 Rb/IgG 1:100 (Jicha et al., 1999b)
AD2 p- Ser-396/p-Ser-404 Mo/IgG 1:500 (Buee-Scherrer et al., 1996)
pS422 p-Ser-422 Rb/IgG 1:1000 (Bussiere et al., 1999)
(E) C-TERMINAL TRUNCATION EPITOPES
TauC3 C-terminal truncation at Asp-421 Mo/IgG 1:1000 (Gamblin et al., 2003c)
mAb 423 C-terminal truncation at Glu-391 Mo/IgG 1:20 (Novak, 1994)
Abbreviations: Mo, mouse; Rb, rabbit; IgG, immunoglobulin G; IgM, immunoglobulin M.
FIGURE 1 | Tau protein domains and location of antibody epitopes. The
schematic representation shows three domains of tau protein and the location
of epitopes for the antibodies used in this study. It is depicted as the longest tau
isoform in the central nervous system of 441 amino acids (grey). Inserts from
alternatively spliced exons are denoted in pink. There are two in the N-terminus
and one in the tandem repeat domain; the other 3 repeat domains are shown in
green. Non-phospho-dependent epitopes are shown above the drawing,
whereas phospho-dependent epitopes are indicated below. Details for
antibodies are listed in Table 2. In green are depicted the repeat domains of tau
protein and gray is the tau protein amino acid sequence.
(TRITC) and blue (CY5). Fluorochromes were excited at
488 nm (for FITC), 540 nm (for TRITC) and 650 nm (for
CY5).
One hundred images in the areas studied for each combination
of antibodies were analyzed (Table 3). From each field in 100× oil
objective, we quantified the number of NFTs in both channels and
the percentage of colocalization of the signal for all channels. The
fields were randomly chosen within the sections. Colocalization
analysis was carried out by quantifying the total number of neu-
rons positive for tau protein phosphorylated at S396 and the
percentage value of neurons positive to other tau markers, includ-
ing: Tau-12, T46, TauC3, AD2, and mAb 423, were determined
to make 100 visual fields at 100×. The data was normalized
to a percentage measure of the number of tau pS396-positive
cells that were simultaneously recognized by other tau epitope
analyzed.
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Table 3 | Proportion of NFTs co-labeled with pS396 and other tau
antibodies.
Antibody combination Co-localization of antibodies in NFTs (%)*
pS396/Tau-12 7.0
pS396/T46 6.6
pS396/TauC3 47.0
pS396/AD2 83.8
pS396/mAb 423 85.7
*Co-localization measured for 100 fields at 100× magnification.
RESULTS
DOUBLE IMMUNOLABELING OF NFTs WITH pS396 AND AD2,
COUNTERSTAINED WITH THIAZIN RED
It has been shown that the antibodies AD2 and pS396, having
similar epitopes, display a similar pattern of immunoreactiv-
ity in tangles (Buee-Scherrer et al., 1996; Galván et al., 2001;
Augustinack et al., 2002; Mondragon-Rodriguez et al., 2008).
Through double-labeling experiments with AD2 and pS396, we
defined two sub-populations of NFTs: one was characterized by
the co-localization of pS396 and TR (Figures 2A,B) but lack-
ing AD2 immunolabeling (Figure 2B); the other sub-population
of NFTs was distinguished by the co-localization of all three
markers (AD2, pS396, and TR). The co-localization of the lat-
ter combination of antibodies was strongest in the proximal
processes of neurons (Figure 2A; arrowhead). Analysis of pS396
and AD2 double-immunolabeled sections showed that there was
co-localization in 84% of tangles (Table 3).
DOUBLE IMMUNOLABELING WITH TauC3 AND pS396 IN NFTs
Truncation at Asp-421, detected using mAb TauC3, is an early
event in tau processing in pre-tangle cells (Rissman et al., 2004;
Luna-Munoz et al., 2007; Mena and Luna-muñoz, 2009). In this
study, we analyzed the spatial association between pS396 and
TauC3 antibodies in NFTs and pre-tangle cells. While the NFT
observed in Figure 2C was detected by both antibodies, the tan-
gle observed in Figure 2D was detected only by pS396. Taking
into account that the tangle in Figure 2C is intracellular, whereas
that in Figure 2D is extracellular, we conclude that the epitope
identified by pS396 was more resistant to the extracellular pro-
teolysis than the epitope detected by TauC3. There was 47% of
co-localization observed in the NFTs labeled with pS396 and
TauC3 (Table 3).
TRIPLE IMMUNOLABELING OF NFTs
To determine whether phosphorylation at pS396 was associated
with full-length tau, we performed triple immunolabeling with
the antibodies for pS396 together with Alz-50 and either Tau-12
or T46 (to non-phosphorylated N- and C- termini, respectively).
Alz-50 was included as a marker of conformational changes in
the tau molecule. We have previously demonstrated the loss of
both C- and N- termini in the protein conformation identified by
Alz-50 and that these changes are associated with early events of
tau processing present in pre-tangle neuronal cells (Jicha et al.,
1997a,b, 1999a; Weaver et al., 2000; Guillozet-Bongaarts et al.,
2005; Luna-Munoz et al., 2007). pS396 immunoreactivity (green
FIGURE 2 | Double and triple immunolabeling of tangles with
antibodies. Intracellular NFTs were detected by both pS396 and AD2 (A).
Extracellular NFTs, however, displayed intense immunoreactivity with
pS396 but only sparse and granular staining with AD2 (B, arrowheads).
Thiazin red detected some PHF bundles located at the center of both intra-
and extra-cellular NFTs (A,B, arrows). Double immunolabeling with TauC3
and pS396 identified two tangle subtypes: one in which both antibodies
were co-localized (C) and another that was reactive only with pS396 (D).
TauC3 immunoreactivity was restricted to short, thin neurites located in the
vicinity of NFTs (arrowheads). Triple immunolabeling with pS396 and Alz-50
with either Tau-12 (E,F) or T46 (G,H); and double immunolabeling with
pS396 and AD2, counterstained with thiazin red (A,B); and pS396 with
TauC3 (C,D). Two subtypes of tangles were observed. (i) The first was
recognized by pS396 (green), but not by Alz-50 (blue) either with Tau-12
(red) (E) or with T46 (red) (G). (ii) A second subtype was defined as the one
which displayed immunoreactivity with all three markers (F,H).
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channel) was present in tangles which were not labeled by Tau-12
(Figure 2E, red channel), T46 (Figure 2G, red channel) or Alz-
50 (Figures 2E,G, blue channel). A sub-population of tangles,
however, displayed immunoreactivity with all three antibodies
(Figures 2F,H). These findings suggest that the epitopes of anti-
bodies Tau-12, T46 and Alz-50 but not that of pS396, are lost
during the early stages of tangle formation. For pS396 with AD2
and TauC3, a high level of co-localization in tangles was observed.
This was in contrast to the low level of co-localization (6–7%) of
pS396 with N- and C-termini (Tau-12 and T46) (Table 3).
DOUBLE IMMUNOLABELING WITH pS396 AND mAb 423 IN EARLY
INTRACELLULAR TANGLES
The labeling of intracellular tangles showed co-localization for
pS396 and mAb 423 immunoreactivity, as previously described
(Garcia-Sierra et al., 2003, 2008). In these early tangles, pS396
immunoreactivity was observed either in an isolated form
in the perinuclear area or organized in net-like structures
(Figure 3A, arrow). The mAb 423 failed to identify these
structures (Figure 3A, arrow).
FIGURE 3 | Double and triple immunolabeling with pS396 and mAb
423, and Alz-50 in neuronal cells with tau degeneration in Alzheimer’s
disease. (A) pS396 immunoreactivity was observed in the intracellular early
tangles, being present in the perinuclear area (arrows) and closely
associated with lipofuscin (arrow, red channel). The mAb 423 failed to
identify these structures (red channel, B, C, D) In tissue pre-treated with
Pronase/formic acid, pS396 and mAb 423 antibodies co-localized in early
tangles (B, arrows), confluent tangle bundles (C, arrows), and NFT (D,
arrow). (E, F) Triple immunolabeling with mAb 423, pS396, and Alz-50 in
Pronase/formic acid treated brain tissue, show all three antibodies
co-localized in the intracellular tangle (E). An extracellular tangle (F)
displayed immunoreactivity with only mAb 423. ∗ lipofuscin granules.
DOUBLE IMMUNOLABELING WITH pS396 AND mAb 423 IN
ALZHEIMER’S DISEASE TISSUE PRE-TREATED WITH PRONASE/FORMIC
ACID IN EARLY TANGLES
When brain tissue was treated with Pronase and formic acid
prior to immunohistochemistry, mAb 423 immunoreactivity
was observed in early tangles and was co-localized with pS396
(Figure 3B, arrows). Clustered, doubly labeled, early tangles
were regularly observed. Double immunolabeling was also found
in elongated tangle bundles that were associated with auto-
fluorescent lipofuscin granules located in the vicinity (Figure 3C,
arrow). Some isolated early tangles were detected only by pS396
(Figure 3C, arrowheads). Extracellular tangles were frequently
labeled by both pS396 and mAb 423 (Figure 2H, arrow). Eighty-
six percent of tangles showed co-localization of these two anti-
bodies (Table 3). The remaining tangles were labeled only bymAb
423, indicating that these were extracellular NFTs.
TRIPLE IMMUNOLABELING WITH ANTIBODIES pS396, mAb 423 AND
Alz-50 IN PRONASE/FORMIC ACID PRE-TREATED BRAIN TISSUE IN
NFTs
An intracellular tangle detected by the mAb 423, pS396, and
Alz-50 is shown in Figure 3E. There was a trend, however, for
the Alz-50 immunoreactivity to be slightly stronger when com-
pared with that of mAb 423 and pS396. Alz-50 and TG-3 are
specific markers of intracellular NFTs (Jicha et al., 1997a), and
the presence of these two epitopes has been implicated in the
early stages of tangle formation (Luna-Munoz et al., 2005). A sub-
population of extracellular NFTs was identified by mAb 423 but
not by pS396, as illustrated in Figure 3F.
TRIPLE IMMUNOLABELING WITH ANTIBODIES mAb 423, pS396, AND
Alz-50 IN PRONASE/FORMIC ACID-TREATED BRAIN TISSUE IN
PRE-TANGLE CELLS
When we performed triple immunolabeling with mAb 423,
pS396, and Alz-50 in Pronase/formic acid-treated brain tissue,
pre-tangle cells, such as the one illustrated in Figure 4, displayed
a diffuse granular cytoplasmic immunolabeling with mAb 423
(green channel) and Alz-50 (blue channel), but were not reac-
tive with pS396 (red channel). Although many immunolabeled
granular deposits were detected by mAb 423 alone, the majority
of such structures that were immunolabeled by Alz-50 were also
detected by mAb 423. Some neurons show cytoplasmic clusters of
granular appearance.
In early investigations, combining confocal microscopy and
electronmicroscopy, we were able to demonstrate that mAb 423
immunoreactivity was present in a diffuse granular pattern in
the cytoplasm of putative pre-tangle cells (Mena et al., 1991,
1995), although this immunolabeled pattern has been difficult
to find. After the Pronase/formic acid procedure, however, mAb
423 immunoreactivity was revealed in diffuse granular struc-
tures in the perinuclear area of the neuronal cell (Figure 4A;
arrows). Some of these structures also co-localize with Alz-50
immunoreactivity (Figure 4C; arrows).
DISCUSSION
The present investigation was focused on the analysis of tau
protein processing and aggregation in neuronal soma from the
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FIGURE 4 | Triple immunolabeling with antibodies mAb 423, pS396,
and Alz-50 of pre-tangle cells after Pronase/formic acid treatment.
(A–D) Triple labeling with mAb 423 (green), Alz-50 (blue) and pS396 (red). A
pre-tangle cell displayed diffuse granular cytoplasmic immunolabeling with
mAb 423 in the green channel (arrows) the majority of which was also
detected by Alz-50 in the blue channel (B; arrows). However, pS396 failed
to detect such granular structures in the red channel (B). Autofluorescent
lipofuscin granules were also observed (∗). N, nucleus.
earliest stages (pre-tangle) of granular aggregation prior to the
formation of PHFs, which are the components of intracellular and
extracellular NFTs. Although NFTs are the structures that best
correlate with the evolution of dementia in Alzheimer’s disease,
we were interested in addressing the early steps involved in their
formation.
Our aim was to study the processing and aggregation of tau
protein in the neuronal soma at early stages (pre-tangle) to deter-
mine the functional role of phosphorylated and truncated tau in
the aggregation process at the cellular level.
We previously described that tau protein undergoes a cascade
of events in Alzheimer’s disease characterized by phosphorylation
at specific sites and conformational changes along its N-terminus
in pre-tangle neurons (Luna-Munoz et al., 2007). In this report,
we have examined early events in tau protein processing along the
C-terminal domain of tau and describe that, with the exception
of phosphorylation at p-Ser-422, phospho-dependent tau epi-
topes were not associated with C-terminal truncation at Glu-391.
Reactivity with mAb 423 was also absent from these structures.
Interestingly, mAb 423 immunoreactivity was evident as granu-
lar diffuse deposits in pre-tangle cells after pre-treatment with
Pronase/formic acid (Figure 4A), whereas immunoreactivity with
pS396, pS400, pS404, and pS409 was absent in these conditions.
Immunoreactivity with these C-terminal, phospho-dependent
antibodies was observed in structures that represent tau protein
aggregation in the pre-tangle stage (Luna-Munoz et al., 2007;
Mena and Luna-muñoz, 2009).
The findings described here and in our earlier studies are
summarized in a scheme that links the histological observations
with the molecular changes in tau protein (Figure 5). Tau protein
is predominantly found associated with axonal microtubules in
unaffected neurons (Stage 0) but in Alzheimer’s disease it accu-
mulates in the somatodendritic compartment of neurons (Binder
et al., 1985). The scheme in Figure 5 depicts this process through
six stages that are characterized by differential immunore-
activity with antibodies to distinct epitopes along the tau
molecule.
The first abnormal event, occurring in the cytoplasm of
neuronal cells prone to degeneration in Alzheimer’s disease, is
characterized by the appearance of the minimal PHF-tau core
unit (truncated at Glu-391) within the cytoplasm (Stage 1).
This pathological event appears to determine subsequent stages
that are characterized by the binding of intact tau molecules to
the PHF core. An early series of phosphorylation events, first
observed along the N-terminus (Stage 2) (Luna-Munoz et al.,
2007; Mena and Luna-muñoz, 2009), would favor the action of
caspase-3 that cleaves at Asp-421 (Gamblin et al., 2003c) (Stage
3). These initial steps would go undetected by TR (Uchihara et al.,
2001; Luna-Munoz et al., 2007) because the early clusters of both
aggregated and less polymerized tau molecules leading to the for-
mation of proto-PHF (tau oligomers of different lengths) (Mena
and Luna-muñoz, 2009) are still randomly distributed and do
not have fully formed β-pleated sheet conformational structures
(Jicha et al., 1997a,b, 1999a; Uchihara et al., 2001). Thus, they
have insufficient affinity for the binding of TR (Jicha et al., 1997b;
Uchihara et al., 2001; Luna-Munoz et al., 2005). The resultant
tau oligomers would act as a template that grows bi-directionally
as further tau molecules become sequestered and structurally
integrated into the proto-PHF.
According to previous studies of pre-tangles (Mena et al.,
1996; Galván et al., 2001; Luna-Munoz et al., 2005), membra-
nous organelles, including mitochondria, nucleus and rough
endoplasmic reticulum could serve as a substrate on which the
emerging proto-PHF could grow, providing proteolytic stabil-
ity during elongation of the assembled filaments (Galván et al.,
2001). The ability of C-terminally truncated PHF-core tau to
capture full-length tau in vitro enables sequential cycles of bind-
ing, truncation and binding. The origin of this process is not
known, but it does not necessarily need to be restricted to a
single specific membrane protein alteration; several different pro-
teins or macromolecular complexes could serve as substrates for
the initial binding of tau protein. After the initial capture of
tau and its proteolysis, the truncated PHF-core tau can bind
further tau molecules with increased avidity (Wischik et al.,
1996), generating oligomeric aggregates that eventually develop
into fibrillary aggregates. Truncation at Glu-391, would confer
a special conformation to enable the formation of PHFs, their
anti-parallel structural alignment and the restriction of access for
the proteolytic enzymes to these oligomers/aggregates/filaments
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FIGURE 5 | A model for the stages of tau assembly into PHFs in
pre-tangle neurons in Alzheimer’s disease. Unaffected neurons (Stage 0)
will have normal tau (neither truncated or hyperphosphorylated) that is
associated predominantly with axonal microtubules. Stages 1–3 represent
early stages that precede the appearance of fibrillary inclusions. Stage 1 is
characterized by the appearance of the PHF core, namely a fragment of
93–95 amino acids in length corresponding to the repeat domain of tau. Stage
2 is defined by the cytoplasmic aggregation of tau molecules resulting from
the binding of PHF-core fragments with full-length tau and that is reactive
with the N-terminal phospho-dependent antibody. This stage corresponds to
the diffuse granular structures seen by confocal microscopy. The PHF-core
tau is not evident at this stage, but can be exposed after Pronase/formic acid
treatment. Stage 3 corresponds to a further stage in which C-terminal
truncation at Asp-421 appears. By Stage 4, intracellular PHFs and fibrils are
present, which are phosphorylated at both N- and C-termini and showed
variable immunoreactivity to mAb 423. The fibrillar nature of the tangles was
confirmed by labeling with TR. As the tangle develops intracellularly in Stage
5, the N-terminal portions are removed and proteolysis reveals the epitope
recognized by mAb 423. By Stage 6, the plasma membrane has been
disrupted and the extracellular “ghost” tangles are evident, which are
comprised of highly insoluble tau, reactive with mAb 423 but with only
occasional pS396 epitopes remaining. See text for more detailed description.
in affected cells (Wischik et al., 1996). Fragments of tau trun-
cated at Glu-391 favor tau polymerization in Alzheimer’s disease
(Wischik et al., 1996; Berry et al., 2003; Gamblin et al., 2003b).
In early tangles, the C-terminal portion of tau would be phos-
phorylated at Ser-396, Ser-400, Ser-404 and Ser-409 (Stage 4).
Interestingly, phosphorylation at Ser-396 seems to be very stable
and co-localizes with the PHF core (mAb 423) in the later stages
of NFT formation, even after neuronal death (Stages 5 and 6).
The proposed model explaining early mechanisms of tau
aggregation in pre-tangle cells, prior to its polymerization into
PHFs, deals with two different issues: the toxic and neuroprotec-
tive capacities of tau protein (Gamblin et al., 2003a; Castellani
et al., 2008; Congdon and Duff, 2008; Garcia-Sierra et al., 2008;
Wang and Liu, 2008; Nunomura et al., 2009). Based upon our
findings and those from other studies, we propose a model that
integrates these processes together with the events of truncation
and phosphorylation. We propose that the polymerization of tau
protein into PHFs, in Alzheimer’s disease, involves complex inter-
actions of truncated and phosphorylated tau species within the
cytoplasm of vulnerable neurons (Zilkova et al., 2011). The toxic
PHF-core tau fragment would be expected to trigger a cellu-
lar protective response, including phosphorylation of normal tau
protein and activation of caspases, including caspase-3 (Fasulo
et al., 2000, 2005; Gamblin et al., 2003c). Once sequestered in a
highly stable and resistant PHF core, full-length tau protein would
then become phosphorylated, thereby hiding the toxic species
(Bretteville and Planel, 2008; Castellani et al., 2008; Su et al., 2008;
Wang and Liu, 2008; Zhang et al., 2009).
This implies that phosphorylation in the early stages of PHF
formation would play a protective role, based upon in vitro
and animal models (Arendt et al., 2003; Stieler et al., 2009,
2011). Moreover tau hyperphosphorylation had been proposed
as a protective mechanism, because it is known that this phe-
nomenon could occur in normal (no pathological) conditions,
such as during development or hibernation, and in these cases tau
hyperphosphorylation does not lead to aggregation or neurode-
generation (Goedert et al., 1993; Arendt et al., 2003; Bretteville
and Planel, 2008).
It is important to emphasize that the phosphorylation of the
N-terminal portion of the protein tau is a very early event in tau
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aggregation and abnormal accumulation in Alzheimer’s disease
(Luna-Munoz et al., 2005, 2007). However, our observations in
all Alzheimer’s disease cases analyzed here showed that tau phos-
phorylation at the C-terminus appears to be associated with early
stages of tau aggregation when the formation of small TR-reactive
tangles occurs. Tau phosphorylation at Ser-422 is observed from
the earliest stages of tau aggregation. Previous studies suggested
that tau phosphorylation at the Ser-422 can prevent the action of
caspase-3, which is very active in Alzheimer’s disease and trun-
cates tau at Asp-421 (Guillozet-Bongaarts et al., 2006). Truncated
tau is present from early to late stages of tau aggregation. This
is why we considered that tau processing and phosphorylation
occurs throughout the entire formation and evolution of the
NFTs. Two events are relevant for this process: 1) tau processing
and 2) sequestration of intact tau and its phosphorylation. This
implies that the more internal epitopes of the NFT are the more
stable and resistant to proteolysis and not necessarily the last to
have been generated. These epitopes could be present through-
out the evolution of the NFT, and they become more evident
when the NFTs have been treated with Pronase/formic acid, thus
exposing the PHF core. In a single tangle, it is possible to find
many different tau epitopes corresponding to various stages of
processing and phosphorylation of tau protein. Thus, NFTs and
pre-tangle structures can be considered as dynamic structures
in which multiple pathological processes occur that affect tau
protein.
In addition, as proposed by Bondareff and colleagues, a pro-
gressive sequence of binding and proteolysis, would eventually
provide a template upon which further intact tau molecules can
be incorporated into the PHF core and become phosphorylated
(Bondareff et al., 1990). Because of the proteolytically resistant
conformation adopted by emerging oligomers, all those char-
acterized by Glu-391 truncation would form PHFs. A similar
cascade of events will characterize the formation of the NFTs.
The predicted effect of both phosphorylation and NFT forma-
tion would be the protection of the neuron (Morsch et al., 1999).
Eventually, however, the tangled-neuron would die because of
abnormal metabolism and/or the release of NFTs into the extra-
cellular space (Mena et al., 1996; Garcia-Sierra et al., 2003; Mena
and Luna-muñoz, 2009). The subsequent action of proteolytic
enzymes would expose the PHF core as the ghost or extracel-
lular NFT appears (Garcia-Sierra et al., 2003, 2008; Guillozet-
Bongaarts et al., 2005). It remains to be determined whether
NFTs, purified from Alzheimer’s disease brains, are toxic. These
studies, however, provide important insight into the characteri-
zation of tau aggregates as they exist in vivo.
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